Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH invested approximately $1.7 million in Amicus Therapeutics, acquiring 212,745 shares in the 1st quarter, representing a 0.07% stake in the company.
• Amicus Therapeutics' stock saw a 5.5% increase to $6.32, with a market cap of $1.95 billion and diverse analyst ratings, including a "buy" rating with a target price increase from $21 to $22 by UBS Group.
• Numerous large investors, including Vanguard Group Inc. and Nuveen Asset Management LLC, have increased their holdings in Amicus Therapeutics during the 4th quarter, indicating growing institutional interest in the stock.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 212,745 shares of the biopharmaceutical company's stock, valued at approximately $1,736,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.07% of Amicus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Virtus Fund Advisers LLC bought a new stake in Amicus Therapeutics in the fourth quarter worth $29,000. Covestor Ltd raised its position in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Amicus Therapeutics in the fourth quarter worth about $59,000. GAMMA Investing LLC raised its position in Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 7,007 shares in the last quarter. Finally, Thrivent Financial for Lutherans acquired a new position in Amicus Therapeutics in the fourth quarter worth about $104,000.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD traded up $0.44 during trading on Monday, reaching $6.76. The company had a trading volume of 1,962,962 shares, compared to its average volume of 3,830,125. The company has a fifty day moving average of $6.05 and a two-hundred day moving average of $7.42. The stock has a market capitalization of $2.08 billion, a P/E ratio of -56.29 and a beta of 0.53. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $12.65. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92.

Analyst Ratings Changes

FOLD has been the subject of several recent analyst reports. UBS Group raised their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. The Goldman Sachs Group lowered their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.